Literature DB >> 11193821

Differential activation of phospholipase D by VPAC and PAC1 receptors.

D A McCulloch1, E M Lutz, M S Johnson, C J MacKenzie, R Mitchell.   

Abstract

To investigate the phospholipase D (PLD) responses of the VIP/PACAP receptors, VPAC1 and VPAC2, and the PACAP-specific PAC1 receptors (short and "hop" intracellular loop 3 (i3) splice variants), stable CHO cell lines expressing similar levels of each wildtype receptor were generated (except for the VPAC1 receptor clone which showed considerably lower expression and lesser responses in signalling assays). All clones caused activation of PLD in response to agonists, as monitored by [3H]phosphatidylbutanol production. The PLD responses of the PAC1 "hop", but not the "null" receptor, were sensitive to the ARF inhibitor, brefeldin A (BFA) (as were VPAC1 and VPAC2 responses). Chimeric constructs of VPAC2 receptors containing i3 of either PAC1 hop or PAC1 null receptors were transiently expressed in COS 7 cells and PLD responses were measured. Only the PLD response of the hop construct was sensitive to BFA. This suggests that i3 motifs in certain Group II GPCRs may play a key role in determining their linkage to ARF-dependent PLD activation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11193821     DOI: 10.1111/j.1749-6632.2000.tb06964.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  9 in total

Review 1.  Pituitary adenylate cyclase-activating polypeptide receptors in the trigeminovascular system: implications for migraine.

Authors:  Tahlia Sundrum; Christopher S Walker
Journal:  Br J Pharmacol       Date:  2017-10-25       Impact factor: 8.739

2.  Signaling pathways and promoter regions that mediate pituitary adenylate cyclase activating polypeptide (PACAP) self-regulation in gonadotrophs.

Authors:  Rongquiang Yang; Stephen J Winters; Joseph P Moore
Journal:  Mol Cell Endocrinol       Date:  2020-05-18       Impact factor: 4.102

3.  Possible key residues that determine left gastric artery blood flow response to PACAP in dogs.

Authors:  Mu-Xin Wei; Ping Hu; Ping Wang; Satoru Naruse; Kiyoshi Nokihara; Victor Wray; Tsuyoshi Ozaki
Journal:  World J Gastroenterol       Date:  2010-10-14       Impact factor: 5.742

4.  The involvement of PACAP/VIP system in the synaptic transmission in the hippocampus.

Authors:  Kai Yang; Gang Lei; Michael F Jackson; John F Macdonald
Journal:  J Mol Neurosci       Date:  2010-04-23       Impact factor: 3.444

Review 5.  Therapeutic potential of vasoactive intestinal peptide and its receptors in neurological disorders.

Authors:  Caitlin M White; Sunggoan Ji; Huan Cai; Stuart Maudsley; Bronwen Martin
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-11       Impact factor: 4.388

6.  Stimulatory and suppressive signal transduction regulates vasoactive intestinal peptide receptor-1 (VPAC-1) in primary mouse CD4 T cells.

Authors:  Emilie E Vomhof-DeKrey; Glenn Paul Dorsam
Journal:  Brain Behav Immun       Date:  2008-06-13       Impact factor: 7.217

Review 7.  Targeting VIP and PACAP Receptor Signaling: New Insights into Designing Drugs for the PACAP Subfamily of Receptors.

Authors:  Jessica Lu; Sarah J Piper; Peishen Zhao; Laurence J Miller; Denise Wootten; Patrick M Sexton
Journal:  Int J Mol Sci       Date:  2022-07-22       Impact factor: 6.208

8.  Mechanisms involved in VPAC receptors activation and regulation: lessons from pharmacological and mutagenesis studies.

Authors:  Ingrid Langer
Journal:  Front Endocrinol (Lausanne)       Date:  2012-10-30       Impact factor: 5.555

Review 9.  A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases.

Authors:  Carmen Martínez; Yasmina Juarranz; Irene Gutiérrez-Cañas; Mar Carrión; Selene Pérez-García; Raúl Villanueva-Romero; David Castro; Amalia Lamana; Mario Mellado; Isidoro González-Álvaro; Rosa P Gomariz
Journal:  Int J Mol Sci       Date:  2019-12-20       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.